1. Home
  2. SOL vs PBYI Comparison

SOL vs PBYI Comparison

Compare SOL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SOL
  • PBYI
  • Stock Information
  • Founded
  • SOL 2005
  • PBYI 2010
  • Country
  • SOL United States
  • PBYI United States
  • Employees
  • SOL N/A
  • PBYI N/A
  • Industry
  • SOL Semiconductors
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • SOL Technology
  • PBYI Health Care
  • Exchange
  • SOL Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • SOL 139.4M
  • PBYI 126.5M
  • IPO Year
  • SOL 2008
  • PBYI N/A
  • Fundamental
  • Price
  • SOL $2.67
  • PBYI $2.85
  • Analyst Decision
  • SOL Buy
  • PBYI Strong Buy
  • Analyst Count
  • SOL 3
  • PBYI 1
  • Target Price
  • SOL $3.83
  • PBYI $7.00
  • AVG Volume (30 Days)
  • SOL 349.7K
  • PBYI 284.4K
  • Earning Date
  • SOL 11-19-2024
  • PBYI 10-31-2024
  • Dividend Yield
  • SOL N/A
  • PBYI N/A
  • EPS Growth
  • SOL N/A
  • PBYI N/A
  • EPS
  • SOL N/A
  • PBYI 0.18
  • Revenue
  • SOL $103,577,000.00
  • PBYI $219,143,000.00
  • Revenue This Year
  • SOL $36.01
  • PBYI N/A
  • Revenue Next Year
  • SOL $28.23
  • PBYI N/A
  • P/E Ratio
  • SOL N/A
  • PBYI $15.66
  • Revenue Growth
  • SOL 7.56
  • PBYI N/A
  • 52 Week Low
  • SOL $1.41
  • PBYI $2.13
  • 52 Week High
  • SOL $3.04
  • PBYI $7.73
  • Technical
  • Relative Strength Index (RSI)
  • SOL 61.00
  • PBYI 62.15
  • Support Level
  • SOL $2.31
  • PBYI $2.41
  • Resistance Level
  • SOL $3.00
  • PBYI $2.71
  • Average True Range (ATR)
  • SOL 0.19
  • PBYI 0.13
  • MACD
  • SOL -0.01
  • PBYI 0.04
  • Stochastic Oscillator
  • SOL 54.79
  • PBYI 100.00

About SOL Emeren Group Ltd each representing 10 shares

Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: